Art­bio rais­es $90M as ra­dio­phar­ma field finds its foot­ing

An­oth­er ra­dio­phar­ma start­up is adding to the field’s buzz with a $90 mil­lion Se­ries A that it plans to use to get in­to the clin­ic and ex­pand its pipeline to five pro­grams.

Art­bio, a transat­lantic biotech work­ing on al­pha ra­di­oli­gand ther­a­pies, said Thurs­day morn­ing that the fi­nanc­ing will bankroll a Phase I next year in PS­MA-di­rect­ed prostate can­cer, which is the same in­di­ca­tion as No­var­tis’ Plu­vic­to and Con­ver­gent Ther­a­peu­tics, an­oth­er start­up that an­nounced a Se­ries A of the same size in May.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER